A small clinical trial shows that semaglutide reduces the number of heavy drinking days in people with this disorder and obesity
A Danish clinical trial involving 108 adults with obesity who were seeking treatment for alcohol use found that a weekly injection of semaglutide reduced the number of heavy drinking days. This decrease averaged about 12 days—50% greater than the eight-day reduction observed in the placebo group. The study is published in The Lancet and was funded by the Novo Nordisk Foundation, the company that develops these drugs.
0